A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

被引：0
|
作者：
Darba, J. [1 ]
Restovic, G. [2 ]
Ramirez de Arellano, A. [3 ]
机构：
[1] Univ Barcelona, Barcelona, Spain
[2] BCN Hlth Econ & Outcomes Res SL, Barcelona, Spain
[3] Roche Farma SA, Madrid, Spain
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66563-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A467 / A467
页数：1
相关论文
共 50 条
  • [21] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
  • [22] Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
    Sherman, Scott K.
    Lange, Joel J.
    Dahdaleh, Fadi S.
    Rajeev, Rahul
    Gamblin, T. Clark
    Polite, Blase N.
    Turaga, Kiran K.
    JAMA ONCOLOGY, 2019, 5 (02) : 236 - 242
  • [23] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE
    Ducournau, P.
    Latimer, N.
    Sabate, E.
    Walzer, S.
    VALUE IN HEALTH, 2008, 11 (06) : A471 - A472
  • [25] Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis
    Barrington, David A.
    Riedinger, Courtney
    Haight, Paulina J.
    Tubbs, Crystal
    Cohn, David E.
    GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 500 - 505
  • [26] TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [27] Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan
    Shiroiwa, Takeru
    Fukuda, Takashi
    Tsutani, Kiichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (03) : 256 - 262
  • [28] Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan
    Takeru Shiroiwa
    Takashi Fukuda
    Kiichiro Tsutani
    International Journal of Clinical Oncology, 2010, 15 : 256 - 262
  • [29] A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer
    Tumeh, John W.
    Shenoy, Pareen J.
    Moore, Susan G.
    Kazrh, John
    Flowers, Christopher
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01): : 49 - 55
  • [30] FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer
    Petrioli, Roberto
    Paolelli, Loretta
    Marsili, Stefania
    Civitelli, Serenella
    Francini, Edoardo
    Cioppa, Tommaso
    Roviello, Franco
    Nettuno, Raffaele
    Intrivici, Chiara
    Tanzini, Gabriello
    Lorenzi, Marco
    Francini, Guido
    ONCOLOGY, 2006, 70 (05) : 345 - 350
12345